Search results for "MESH: Administration"

showing 5 items of 5 documents

Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension:A Double-Blind Placebo-controlled Clinical Trial

2020

Rationale: Oral treprostinil improves exercise capacity in patients with pulmonary arterial hypertension (PAH), but the effect on clinical outcomes was unknown.\ud \ud Objectives: To evaluate the effect of oral treprostinil compared with placebo on time to first adjudicated clinical worsening event in participants with PAH who recently began approved oral monotherapy.\ud \ud Methods: In this event-driven, double-blind study, we randomly allocated 690 participants (1:1 ratio) with PAH to receive placebo or oral treprostinil extended-release tablets three times daily. Eligible participants were using approved oral monotherapy for over 30 days before randomization and had a 6-minute-walk dista…

MaleAdministration OralOral treprostinilCritical Care and Intensive Care MedicinePulmonary arterial hypertension[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tractcombination therapyoralepoprostenol0302 clinical medicinepulmonary arterial hypertensionmiddle agedClinical endpointdouble-blind methodMESH: Double-Blind MethodFamilial Primary Pulmonary Hypertension030212 general & internal medicinehumansMESH: AgedMESH: Middle AgedEpoprostenol/analogs & derivativesadultHazard ratioMiddle Aged[SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciencesantihypertensive agents3. Good healthagedfemaleMESH: Young Adultoral treprostinilMESH: Administration Oralyoung adultFemalePulmonary Arterial Hypertension/drug therapymedicine.drugAdultPulmonary and Respiratory MedicineMESH: Pulmonary Arterial Hypertensionmedicine.medical_specialtyRandomizationAdolescentclinical study; combination therapy; oral treprostinil; pulmonary arterial hypertension; sequential therapy; administration oral; adolescent; adult; aged; antihypertensive agents; double-blind method; epoprostenol; female; humans; male; middle aged; placebos; pulmonary arterial hypertension; young adultSequential therapyMESH: PlacebosMESH: EpoprostenolLower riskPlaceboadministrationClinical studyYoung Adult03 medical and health sciencesDouble-Blind Method[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemmaleInternal medicineplacebosmedicineHumansCombination therapyAdverse effectPlacebos/therapeutic useAgedMESH: AdolescentPulmonary Vascular DiseaseMESH: Antihypertensive AgentsMESH: Humanssequential therapybusiness.industryMESH: AdultOriginal Articlesclinical studyMESH: MaleClinical trial030228 respiratory systemadolescentAntihypertensive Agents/administration & dosagebusinessMESH: FemaleTreprostinil
researchProduct

Rivaroxaban for thromboprophylaxis in acutely ill medical patients.

2013

International audience; BACKGROUND: The clinically appropriate duration of thromboprophylaxis in hospitalized patients with acute medical illnesses is unknown. In this multicenter, randomized, double-blind trial, we evaluated the efficacy and safety of oral rivaroxaban administered for an extended period, as compared with subcutaneous enoxaparin administered for a standard period, followed by placebo. METHODS: We randomly assigned patients 40 years of age or older who were hospitalized for an acute medical illness to receive subcutaneous enoxaparin, 40 mg once daily, for 10±4 days and oral placebo for 35±4 days or to receive subcutaneous placebo for 10±4 days and oral rivaroxaban, 10 mg onc…

MaleMESH: Factor Xa[SDV]Life Sciences [q-bio]Administration Oral030204 cardiovascular system & hematologylaw.inventionMESH: Venous Thromboembolismchemistry.chemical_compound0302 clinical medicineRivaroxabanRandomized controlled triallawMedicineMESH: Double-Blind Method030212 general & internal medicineMESH: AgedMESH: Middle AgedVenous ThromboembolismGeneral MedicineMiddle AgedMESH: Thiophenes3. Good healthAnesthesiaAcute DiseaseMESH: Administration OralMESH: Acute DiseaseFemaleMESH: Hemorrhagemedicine.drugAdultRandomizationMESH: EnoxaparinInjections SubcutaneousMorpholinesMESH: MorpholinesHemorrhageThiophenesMESH: AnticoagulantsMESH: Drug Administration SchedulePlaceboDrug Administration Schedule03 medical and health sciencesDouble-Blind MethodRivaroxaban venous thromboembolismHumansEnoxaparinAgedRivaroxabanMESH: Humansbusiness.industryMESH: Injections SubcutaneousAnticoagulantsMESH: AdultConfidence intervalMESH: MalechemistryBetrixabanRelative riskbusinessVenous thromboembolismMESH: FemaleFactor Xa Inhibitors
researchProduct

Endovascular Stroke Treatment and Risk of Intracranial Hemorrhage in Anticoagulated Patients

2020

Background and Purpose— We aimed to determine the safety and mortality after mechanical thrombectomy in patients taking vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs). Methods— In a multicenter observational cohort study, we used multiple logistic regression analysis to evaluate associations of symptomatic intracranial hemorrhage (sICH) with VKA or DOAC prescription before thrombectomy as compared with no anticoagulation. The primary outcomes were the rate of sICH and all-cause mortality at 90 days, incorporating sensitivity analysis regarding confirmed therapeutic anticoagulation. Additionally, we performed a systematic review and meta-analysis of literature on this to…

MaleMESH: RegistriesAdministration Oral030204 cardiovascular system & hematology0302 clinical medicineInterquartile rangeMESH: ThrombectomyRegistriesStrokeThrombectomyMESH: AgedMESH: Middle AgedMESH: Follow-Up StudiesMiddle Aged3. Good healthddc:StrokeMESH: Administration OralFemale[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]Cardiology and Cardiovascular MedicineMESH: Intracranial HemorrhagesCohort studymedicine.medical_specialty610 Medicine & healthMESH: AnticoagulantsLower riskMESH: Stroke03 medical and health sciencesMeta-Analysis as TopicInternal medicinemedicineHumansMESH: Meta-Analysis as TopicMedical prescriptionAgedAdvanced and Specialized NursingMESH: Humansbusiness.industryAnticoagulantsOdds ratiomedicine.diseaseFactor Xa inhibitorsMESH: MaleStroke treatmentIntracranial hemorrhagesObservational studyNeurology (clinical)MESH: Systematic Reviews as TopicbusinessMESH: Female030217 neurology & neurosurgeryFollow-Up StudiesSystematic Reviews as Topic
researchProduct

Effects of manganese injected into rat nostrils: implications for in vivo functional study of olfaction using MEMRI.

2011

WOS: 000298212500007; International audience; Manganese-enhanced magnetic resonance imaging (MEMRI) is a powerful tool for visualizing neuronal pathways and mapping brain activity modulation. A potential drawback of MEMRI lies in the toxic effects of manganese (Mn), which also depend on its administration route. The aim of this study was to analyze the effects of Mn doses injected into the nostrils of rats on both olfactory perception and MRI contrast enhancement. For this purpose, doses in the range 0-8 μmol MnCl(2) were tested. Behavioral items were quantified with and without odor stimulation during the first 2 h following Mn injection. The MRI study was performed after 16 h of intermitt…

MalePathologyBrain activity and meditation[ SDV.AEN ] Life Sciences [q-bio]/Food and NutritionContrast MediaStimulationPharmacologyMESH : Behavior AnimalMEMRI Manganese030218 nuclear medicine & medical imagingMESH: Magnetic Resonance Imaging0302 clinical medicineMESH: SmellMESH: Behavior AnimalMESH: AnimalsMESH: Administration IntranasalMESH : Olfactory Bulbmedicine.diagnostic_testBehavior AnimalChemistryMESH : RatsMagnetic Resonance ImagingOlfactory BulbSmellDoseToxicityMESH: Image EnhancementMESH: Olfactory Bulbmedicine.medical_specialtyMESH: RatsMESH : MaleBiomedical EngineeringBiophysicsMESH: ManganeseOlfactionMESH : Rats Wistar03 medical and health sciencesPrimary olfactory cortexIn vivoMESH : Magnetic Resonance ImagingMESH: Contrast MediamedicineAnimalsRadiology Nuclear Medicine and imagingRats WistarAdministration IntranasalMESH : Contrast MediaBehaviorManganeseToxicityMESH : Administration IntranasalMagnetic resonance imagingMESH: Rats WistarImage EnhancementOlfactionMESH: MaleRatsOdorRatMESH : SmellMESH : Image EnhancementMESH : AnimalsMESH : Manganese[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition030217 neurology & neurosurgery
researchProduct

Characteristics and treatment regimens across ERS SHARP severe asthma registries

2020

Little is known about the characteristics and treatments of patients with severe asthma across Europe, but both are likely to vary. This is the first study in the European Respiratory Society Severe Heterogeneous Asthma Research collaboration, Patient-centred (SHARP) Clinical Research Collaboration and it is designed to explore these variations. Therefore, we aimed to compare characteristics of patients in European severe asthma registries and treatments before starting biologicals.This was a cross-sectional retrospective analysis of aggregated data from 11 national severe asthma registries that joined SHARP with established patient databases.Analysis of data from 3236 patients showed many …

Severe asthmaPediatricsMESH: RegistriesMESH: AsthmaCross-sectional studyRespiratory SystemMedizin[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract0302 clinical medicineMESH: BelgiumBelgiumMedicine researchAnti-Asthmatic AgentsRegistries030212 general & internal medicine[SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/Allergology10. No inequality11 Medical and Health SciencesNetherlands2. Zero hungereducation.field_of_studySHARP CRCMESH: Administration InhalationMESH: Anti-Asthmatic Agents3. Good healthEuropeItalyMESH: PolandMESH: Swedenmedicine.drugPulmonary and Respiratory Medicinemedicine.medical_specialtyMESH: HungaryPopulationInvestigació mèdicaSettore MED/10 - Malattie Dell'Apparato Respiratorio03 medical and health sciencesMESH: Cross-Sectional StudiesAdministration InhalationMESH: SpainmedicineHumanseducationAsmaRetrospective StudiesAsthmaSwedenHungaryMESH: Humansbusiness.industrySettore MED/09 - MEDICINA INTERNAMESH: ItalyMESH: Retrospective StudiesRetrospective cohort studyOriginal Articlesasthmamedicine.diseaseAsthmaClinical trialCross-Sectional StudiesClinical research030228 respiratory systemSpainMESH: NetherlandsMESH: EuropePolandbusinessBody mass indexMepolizumabEuropean Respiratory Journal
researchProduct